PID | Title | Article | Time | Author | Doi |
---|---|---|---|---|---|
16603771 |
Transcript ID | Name | Length | RefSeq ID | Protein ID | Length | RefSeq ID | UniportKB ID |
---|---|---|---|---|---|---|---|
ENST00000466844 | BAZ1B-203 | 827 | - | - | - (aa) | - | - |
ENST00000404251 | BAZ1B-202 | 5428 | - | ENSP00000385442 | 1483 (aa) | - | Q9UIG0 |
ENST00000339594 | BAZ1B-201 | 6102 | XM_017012773 | ENSP00000342434 | 1483 (aa) | XP_016868262 | Q9UIG0 |
ensgID | Trait | pValue | Pubmed ID |
---|---|---|---|
ENSG00000009954 | Uric Acid | 1E-12 | 23263486 |
ENSG00000009954 | Triglycerides | 2E-12 | 20864672 |
ENSG00000009954 | Triglycerides | 3E-15 | 19060906 |
ENSG00000009954 | Triglycerides | 1E-12 | 19060911 |
ENSG00000009954 | Triglycerides | 1E-16 | 26582766 |
ENSG00000009954 | Triglycerides | 3E-7 | 20139978 |
ENSG00000009954 | Protein C | 3E-8 | 20802025 |
ENSG00000009954 | Hypertriglyceridemia | 3E-6 | 20657596 |
ENSG00000009954 | Hypertriglyceridemia | 8E-9 | 27599772 |
ENSG00000009954 | Migraine Disorders | 3E-8 | 27182965 |
ENSG00000009954 | Blood Pressure | 3E-40 | 27790247 |
ENSG00000009954 | Cholesterol | 3E-40 | 27790247 |
ENSG00000009954 | Electrocardiography | 3E-40 | 27790247 |
ENSG00000009954 | Glucose | 3E-40 | 27790247 |
ENSG00000009954 | Hematocrit | 3E-40 | 27790247 |
ENSG00000009954 | Cholesterol, HDL | 3E-40 | 27790247 |
ENSG00000009954 | Triglycerides | 3E-40 | 27790247 |
ENSG00000009954 | Body Mass Index | 3E-40 | 27790247 |
ENSG00000009954 | Atrial Fibrillation | 1E-17 | 27790247 |
ENSG00000009954 | Blood Pressure | 1E-17 | 27790247 |
ENSG00000009954 | Cholesterol | 1E-17 | 27790247 |
ENSG00000009954 | Coronary Disease | 1E-17 | 27790247 |
ENSG00000009954 | Diabetes Mellitus | 1E-17 | 27790247 |
ENSG00000009954 | Electrocardiography | 1E-17 | 27790247 |
ENSG00000009954 | Glucose | 1E-17 | 27790247 |
ENSG00000009954 | Heart Failure | 1E-17 | 27790247 |
ENSG00000009954 | Hematocrit | 1E-17 | 27790247 |
ENSG00000009954 | Cholesterol, HDL | 1E-17 | 27790247 |
ENSG00000009954 | Mortality | 1E-17 | 27790247 |
ENSG00000009954 | Neoplasms | 1E-17 | 27790247 |
ENSG00000009954 | Triglycerides | 1E-17 | 27790247 |
ENSG00000009954 | Body Mass Index | 1E-17 | 27790247 |
ENSG00000009954 | Stroke | 1E-17 | 27790247 |
ENSG00000009954 | C-Reactive Protein | 1E-13 | 27286809 |
ENSG00000009954 | Cholesterol, HDL | 1E-13 | 27286809 |
ENSG00000009954 | Coffee | 1E-6 | 21490707 |
ensgID | SNP | Chromosome | Position | SNP-risk | Trait | PubmedID | 95% CI | Or or BEAT | EFO ID |
---|---|---|---|---|---|---|---|---|---|
ENSG00000009954 | rs1178979 | 7 | 73442100 | C | Protein C levels | 28082259 | [NR] μg/mL decrease | 0.06 | EFO_0004633 |
ENSG00000009954 | rs13244268 | 7 | 73497513 | T | C-reactive protein levels or HDL-cholesterol levels (pleiotropy) | 27286809 | EFO_0004458|EFO_0004612 | ||
ENSG00000009954 | rs714052 | 7 | 73450539 | G | Triglycerides | 20139978 | [0.076-0.170] unit decrease | 0.123 | EFO_0004530 |
ENSG00000009954 | rs2074755 | 7 | 73462836 | ? | Age-related disease endophenotypes | 27790247 | EFO_0004574|EFO_0006336|EFO_0004530|EFO_0006335|EFO_0004348|EFO_0007928|EFO_0004468|EFO_0004340|EFO_0004612 | ||
ENSG00000009954 | rs13231516 | 7 | 73448919 | T | Triglycerides | 26582766 | [0.022-0.038] unit increase | 0.03 | EFO_0004530 |
ENSG00000009954 | rs1178977 | 7 | 73442719 | A | Urate levels | 23263486 | [0.034-0.06] unit increase | 0.047 | EFO_0004531 |
ENSG00000009954 | rs714052 | 7 | 73450539 | G | Triglycerides | 19060906 | [0.10-0.22] s.d. decrease | 0.16 | EFO_0004530 |
ENSG00000009954 | rs714052 | 7 | 73450539 | ? | Hypertriglyceridemia | 20657596 | [1.61-3.23] | 2.27 | EFO_0004211 |
ENSG00000009954 | rs17145713 | 7 | 73490480 | T | Protein C levels | 20802025 | [0.04-0.08] ug/ml decrease | 0.06 | EFO_0004633 |
ENSG00000009954 | rs1178979 | 7 | 73442100 | A | Triglycerides | 20864672 | [0.03-0.07] unit increase | 0.05 | EFO_0004530 |
ENSG00000009954 | rs2240466 | 7 | 73441939 | G | Triglycerides | 19060911 | [NR] s.d. increase | 0.14 | EFO_0004530 |
ENSG00000009954 | rs2240466 | 7 | 73441939 | A | Caffeine consumption | 21490707 | [0.07-0.15] mg/day increase | 0.1109 | EFO_0004330 |
ENSG00000009954 | rs6976930 | 7 | 73471480 | G | Waist-to-hip ratio adjusted for body mass index | 28448500 | [0.02-0.046] unit increase | 0.0326 | EFO_0007788|EFO_0008002 |
ENSG00000009954 | rs6976930 | 7 | 73471480 | G | Waist-to-hip ratio adjusted for body mass index | 28448500 | [0.019-0.039] unit increase | 0.0294 | EFO_0007788|EFO_0008002 |
ENSG00000009954 | rs6976930 | 7 | 73471480 | G | Waist-to-hip ratio adjusted for BMI in active individuals | 28448500 | [0.02-0.05] unit increase | 0.0351 | EFO_0007788|EFO_0008002 |
ENSG00000009954 | rs6976930 | 7 | 73471480 | G | Waist-to-hip ratio adjusted for BMI in active individuals | 28448500 | [0.021-0.043] unit increase | 0.0319 | EFO_0007788|EFO_0008002 |
ENSG00000009954 | rs202203062 | 7 | 73443388 | ? | Migraine | 27182965 | [1.039-1.083] | 1.061 | EFO_0003821 |
ENSG00000009954 | rs6976930 | 7 | 73471480 | ? | Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) | 28448500 | EFO_0007788|EFO_0008002 | ||
ENSG00000009954 | rs6976930 | 7 | 73471480 | ? | Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) | 28448500 | EFO_0007788|EFO_0008002 | ||
ENSG00000009954 | rs1178977 | 7 | 73442719 | A | Triglyceride levels | 28334899 | [0.087-0.157] unit increase | 0.122 | EFO_0004530 |
ENSG00000009954 | rs7811265 | 7 | 73520180 | A | High density lipoprotein cholesterol levels | 29507422 | unit decrease | 0.034 | EFO_0004612 |
ENSG00000009954 | rs7811265 | 7 | 73520180 | A | High density lipoprotein cholesterol levels | 29507422 | unit decrease | 0.031 | EFO_0004612 |
ENSG00000009954 | rs7811265 | 7 | 73520180 | A | Triglycerides | 29507422 | unit increase | 0.11 | EFO_0004530 |
ENSG00000009954 | rs7811265 | 7 | 73520180 | A | Triglycerides | 29507422 | unit increase | 0.104 | EFO_0004530 |
ENSG00000009954 | rs7811265 | 7 | 73520180 | A | Triglycerides | 29507422 | unit increase | 0.116 | EFO_0004530 |
ENSG00000009954 | rs7811265 | 7 | 73520180 | A | Triglycerides | 29507422 | unit increase | 0.106 | EFO_0004530 |
Go ID | Go_term | PubmedID | Evidence | Category |
---|---|---|---|---|
GO:0000793 | condensed chromosome | - | IEA | Component |
GO:0004713 | protein tyrosine kinase activity | 19092802. | IDA | Function |
GO:0004715 | non-membrane spanning protein tyrosine kinase activity | - | IEA | Function |
GO:0005515 | protein binding | 11980720.15543136.16514417.30021884. | IPI | Function |
GO:0005524 | ATP binding | - | IEA | Function |
GO:0005654 | nucleoplasm | - | TAS | Component |
GO:0005721 | pericentric heterochromatin | - | IEA | Component |
GO:0006333 | chromatin assembly or disassembly | - | IEA | Process |
GO:0006338 | chromatin remodeling | 29021563. | TAS | Process |
GO:0006357 | regulation of transcription by RNA polymerase II | 10662543. | NAS | Process |
GO:0006974 | cellular response to DNA damage stimulus | 19092802. | IDA | Process |
GO:0008270 | zinc ion binding | 11124022. | NAS | Function |
GO:0016572 | histone phosphorylation | 19092802. | IDA | Process |
GO:0016604 | nuclear body | - | IDA | Component |
GO:0018108 | peptidyl-tyrosine phosphorylation | - | IEA | Process |
GO:0035173 | histone kinase activity | 19092802. | IDA | Function |
GO:0042393 | histone binding | - | IEA | Function |
GO:0043596 | nuclear replication fork | 15543136. | IDA | Component |
GO:0045815 | positive regulation of gene expression, epigenetic | - | TAS | Process |